JOP: Journal of the pancreas (J Pancreas )

Description

  • Impact factor
    0.00
  • 5-year impact
    0.00
  • Cited half-life
    0.00
  • Immediacy index
    0.00
  • Eigenfactor
    0.00
  • Article influence
    0.00
  • Website
    Journal of the Pancreas website
  • Other titles
    JOP. Journal of the Pancreas, Journal of the pancreas
  • ISSN
    1590-8577
  • OCLC
    46677991
  • Material type
    Document, Periodical, Internet resource
  • Document type
    Internet Resource, Computer File, Journal / Magazine / Newspaper

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: Positron emission tomography (PET) using 18F-fluorodeoxyglucose (FDG) is increasingly used for the staging of solid malignancies, including lung and esophagus. However, controversy still exists in relation to the application of PET in pancreatic cancer. The authors review seven studies (Abstracts #183, #189, #190, #254, #357, #375, #378) presented at the 2014 ASCO Gastrointestinal Cancers Symposium and discuss on the role of PET in this disease. As the limitations of the Response Evaluation Criteria In Solid Tumors (RECIST) continue to become evident, FDG-PET may identify changes in the metabolic activity within pancreatic adenocarcinoma, and can provide both diagnostic and prognostic information.
    JOP: Journal of the pancreas 01/2014; 15(2):124-7.
  • JOP: Journal of the pancreas 01/2014; 15(3):225-7.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Solitary fibrous tumor of the central nervous system is uncommon, with only around 200 reported cases. Further, extracranial metastasis is extremely rare, and only 5 cases of hematogenous metastases have been reported so far. To the best of our knowledge, there have been no reports of solitary fibrous tumor of the central nervous system metastasizing to the pancreas. A 62-year-old woman was referred for evaluation of a pancreatic mass, which was strongly suspected to be a neuroendocrine tumor. However, the histological findings and immunohistochemical profile indicated the presence of a solitary fibrous tumor. Because the medical history revealed previous transcranial resection for intracranial meningioma 16 years ago, we conducted a pathological review of the brain specimen obtained by the first operation and found that it had the same histology and immunohistochemical profile as the current endoscopic ultrasound-guided fine-needle aspiration specimen. Consequently, the final diagnosis, on the basis of the brain specimen, was changed from meningioma to solitary fibrous tumor of the central nervous system, and the pancreatic mass was diagnosed as metastasis from solitary fibrous tumor of the central nervous system. The patient underwent middle pancreatectomy; the pancreatic specimen also had the same histology and immunohistochemical profile as the brain specimen. Histological findings and immunohistochemical profile obtained by EUS-FNA are invaluable for the correct diagnosis to avoid excessive surgical procedures.
    JOP: Journal of the pancreas 01/2014; 15(1):58-62.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Acute pancreatitis is defined as an acute inflammatory process in the pancreas with variable involvement of other regional tissues or remote organ systems. In Italy, the incidence ranges from 20 to 40 x100,000 inhabitants/year and the mortality rate ranges from 5 to 10%. To assess the management of patients with suspected acute inflammatory pancreatopathy and to evaluate the impact of this management on clinical outcomes, including morbidity and mortality. A "real-world" observational study based on the analysis of consecutive (one year) records from the Hospital Data Processing Centre: 112 cases with final diagnosis of "acute pancreatitis". Sixty-nine men and 43 women were analyzed; 91 (81.3%) patients were older than 40 years and 53 (47.3%) were older than 60 years. Two patients died. One-hundred and five patients (93.8%) had abdominal pain on admission. White blood cell count was greater than 15.0 x103/dL in 26 patients (23.2%). Hematocrit levels were greater than 40% in 30 patients (26.8%). Triglycerides were elevated in 21 patients (18.8%). In 3 of them (14.3%) levels were higher than 1,000 mg/dL. Creatinine was altered in 22 (19.6%) patients. CRP values were increased in all patients. In the majority of cases (58 patients; 51.8%) pancreatitis was of biliary origin, while alcohol accounted for 16 (14.3%) cases. Four tumors were found (3.6%). Forty patients (35.7%) were discharged in the first week, 41 (36.6%) in the second week, 19 (17.0%) in the third week, and 12 (10.7%) after 21 days. After 72 hours, acute pancreatitis was classified as mild in 80 patients (71.4%) and as severe in 32 patients (28.6%).
    JOP: Journal of the pancreas 01/2014; 15(2):175-81.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Corticosteroid is a well-established cause of drug-induced pancreatitis. However, acute pancreatitis from intra-articular injection of corticosteroid has never been described. A 69-year-old male presented with acute abdominal pain and was diagnosed with acute pancreatitis. The patient had one episode of acute pancreatitis two year earlier. Both episodes occurred after intra-articular cortisone injection. Investigations for other causes of pancreatitis were negative. We report the first case of acute pancreatitis from intra-articular corticosteroid injection. Physicians should be aware of this adverse reaction of corticosteroid that can even occur with local administration.
    JOP: Journal of the pancreas 01/2014; 15(2):208-9.
  • [Show abstract] [Hide abstract]
    ABSTRACT: FOLFIRINOX (5-FU, oxaliplatin and irinotecan) and gemcitabine based regimens are widely used for the first-line treatment for patients with advanced pancreatic adenocarcinoma. Nab-paclitaxel and gemcitabine has replaced the use of many single agent gemcitabine in these patients population. In patients who progress on the first line therapy use of either 5-FU, leucovorin and oxaliplatin (FOLFOX) or gemcitabine and nab-paclitaxel combination has become a de facto standard depending on the chemotherapy they received in first line. Progress made in first line chemotherapy has lead to more interest in refractory pancreatic cancer. This article examines the 2014 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium regarding recent developments in the treatment of refractory pancreatic cancer, as these were presented in Abstracts #296, #297, #337, #344, and #381 of the meeting.
    JOP: Journal of the pancreas 01/2014; 15(2):106-9.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pancreatic cancer represents one of the leading causes of cancer related deaths worldwide and constitutes a major public health problem. Despite the advances in diagnosis and treatment, the overall five-year survival remains low, thus leading the focus of medical research towards the identification and modification of potential risk factors. This year, in ASCO Annual Meeting two interesting studies were presented. Ghani et al. (abstract #e15183) sought to investigate the effect of smoking on chemotherapy response in patients with metastatic pancreatic cancer, while Walker et al. (abstract #4117) presented the results of their study regarding the effect of statin use in the prevention of pancreatic cancer. Both studies concluded to useful results that along with the existing literature may further stimulate medical research towards better recognition of risk factors and the application of this knowledge in the clinical practice.
    JOP: Journal of the pancreas 01/2014; 15(4):289-91.
  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the effectiveness of pharmaconutrition-supplemented parenteral nutrition (PN) for severe acute pancreatitis (SAP).
    JOP: Journal of the pancreas 01/2014; 15(4):371-7.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cells in the interior of pancreatic tumors are believed to undergo continual autophagy to maintain homeostasis during unregulated growth in hypoxia caused by impaired vascularity. We hypothesize that treating metastatic cells with chloroquine, an inhibitor of autophagy, in hypoxia will decrease cell viability and induce cell death. MiaPaCa2 (non-metastatic) and S2VP10 (metastatic) cell lines were treated with 25 and 50 µM chloroquine for 24 and 48 hours in normoxia and hypoxia (5-10% O2). Viability was measured using ATPliteTM. After treatment, the cell stress was analyzed, and protein was lysed and quantified using the Bradford assay. Autophagy-associated protein levels were determined by Western blot. S2VP10 cells treated for 48 hours with 50 μM chloroquine in hypoxia had 24% viability compared to normoxia control, with loss of 10% viability caused by low O2 alone. MiaPaCa2 cells under these conditions had 60% viability compared to normoxia control, with loss of 25% viability caused by low O2 alone. Analysis of cell stress pathways and dosimetry of Western blot data suggest that chloroquine inhibits the autophagy pathway in the metastatic S2VP10 cells. Autophagy blockage with chloroquine or similar-acting drugs may serve as a viable therapy for highly metastatic pancreatic cancers.
    JOP: Journal of the pancreas 01/2014; 15(2):189-97.
  • JOP: Journal of the pancreas 01/2014; 15(4):411-2.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Surgery remains the only curative treatment for pancreatic cancer; however, majority of patients present with advanced unresectable disease upon diagnosis. Treatment of nonmetastatic, locally advanced pancreatic cancer (LAPC) continues to require multidisciplinary bimodality or trimodality approach. Neoadjuvant therapies have been investigated for LAPC given its established role in other solid cancers such as breast cancer, gastric cancer, and rectal cancer. This strategy is now moving forward to management of potentially resectable disease as well. This meeting highlight focuses on recent updates on neoadjuvant therapy for both borderline resectable disease and potentially resectable disease, Abstracts #4120, #e15189, #e15226 and #TPS4158 will be discussed.
    JOP: Journal of the pancreas 01/2014; 15(4):354-7.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The natural history of incidental branch-duct intraductal papillary mucinous neoplasm of the pancreas is still unknown.
    JOP: Journal of the pancreas 01/2014; 15(4):391-3.
  • JOP: Journal of the pancreas 01/2014; 15(1):2063.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pancreatic cancer is the fourth leading cause of cancer-related deaths in United States. Despite advances in understanding cancer biology and therapeutics, this malignancy carries a grave prognosis with a poor overall survival rate. This is especially true for patients with locally advanced and metastatic disease that are not amenable to surgical resection. Given advances in human genome sequencing and pharmacogenomics, we now better understand the complex genetic makeup of these tumors and numerous gene mutations have been identified that could be potential targets for drug development. In this review, we discuss two abstract (Abstracts #208 and #192) presented at the 2014 ASCO Gastrointestinal Cancers Symposium about pancreatic cancer genome sequencing and their implications for the future of this disease. We discuss what is known about the genome of pancreatic tumors, including common mutations like KRAS, TP53 and SMAD4, as well as discovery of additional mutations. In particular, KRAS2 mutations in a subset of patients with pancreatic cancer are discussed. While limited in size and clinical correlativity, these abstracts provide at least seven novel/targetable mutations and elucidate biologic differences in tumors with wild type and mutant KRAS. These are important steps in understanding tumor biology and genetic basis of pancreatic cancer to help develop targeted drug therapies in the fast approaching era of personalized medicine.
    JOP: Journal of the pancreas 01/2014; 15(2):114-7.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Gastroenteropancreatic neuroendocrine tumors are a heterogeneous group of carcinomas that remain difficult to treat with conventional cytotoxic regimens. The 2014 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium brought us new insights into the management of gastroenteropancreatic neuroendocrine tumors. The focus of this review will serve to highlight specific Abstracts (#268 and #273) that help shed light on a novel, targeted means of treating gastroenteropancreatic neuroendocrine tumors.
    JOP: Journal of the pancreas 01/2014; 15(2):135-7.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Development of a second primary malignancy after an index esophageal cancer is a rare event, primarily due to short survival of patients with esophageal cancer. However, the number of long-term esophageal cancer survivors has been increasing due to advances in early detection and therapy. We report herein a case of pancreatic adenocarcinoma that developed three years after a successfully treated early-stage adenocarcinoma of the esophagus. A 70-year-old Caucasian male presented with vague complaints of nausea, vomiting and abdominal distention, with subsequent development of jaundice. A computed tomography scan of abdomen revealed a 2.9 cm soft tissue mass in the head of the pancreas and the patient underwent a Whipple's procedure, with pathology confirming the diagnosis of pancreatic adenocarcinoma. Three years previously, the patient was successfully treated for adenocarcinoma of the esophagus via minimally invasive esophagogastrectomy. Despite chemoradiotherapy for localized disease and subsequent systemic chemotherapy for metastatic pancreatic cancer, the patient eventually succumbed to his illness. We discuss the association between esophageal cancer and subsequent second malignancies, along with implications for surveillance and therapy.
    JOP: Journal of the pancreas 01/2014; 15(1):46-8.

Related Journals